Can Wegovy Affect Your Eyesight? Vision Side Effects Explained

What is NAION, and why has it appeared in semaglutide safety discussions?

Non-arteritic anterior ischaemic optic neuropathy is a condition where blood supply to the optic nerve is suddenly interrupted. It is not unique to GLP-1 medicines, it occurs in the general population, most commonly in people over 50 with small optic discs, high blood pressure, or diabetes. What changed the conversation was a study published in JAMA Ophthalmology in 2024, which compared electronic health records of patients with type 2 diabetes or obesity who were taking semaglutide against those taking other medicines. The researchers found a notably higher rate of NAION diagnoses in the semaglutide group.

The MHRA has added this signal to its ongoing monitoring for semaglutide-containing medicines, including Wegovy. The absolute numbers remain small (this is not a common outcome) but the potential for permanent vision loss means it cannot be treated as a minor side effect. A question our prescribers hear most weeks is whether this rules Wegovy out for everyone with a history of eye problems; the honest answer is that it depends on your specific history, and it is exactly the kind of detail a prescriber needs to assess before recommending treatment. Pre-existing optic disc conditions or a history of NAION in the other eye may warrant extra caution or a conversation with an ophthalmologist first.

For a thorough overview of semaglutide's full range of eye side effects, the NHS medicines page on semaglutide is the clearest starting point for patients.

What about the blurred vision and other eye symptoms mentioned in Wegovy's trial data?

Separate from NAION, blurred vision was reported by some participants during the STEP clinical trials. This is largely explained by the way semaglutide affects blood glucose. When glucose levels fall relatively quickly (even within the normal, healthy range) the lens of the eye can temporarily change shape, altering how it focuses light. The effect is most common in the early weeks of treatment, when the medicine is having its most pronounced impact on appetite and metabolism.

For people without diabetes this effect is usually mild and self-limiting. It does not mean something is going wrong with the optic nerve. The distinction matters: blurred vision that comes and goes in the first few weeks, settles, and does not affect one eye more than the other is a different clinical picture from the sudden, painless vision loss that signals NAION or another serious optic event.

The full side-effect data (including the rates at which visual disturbances were recorded) is set out in the Wegovy SmPC on the eMC (Electronic Medicines Compendium), which is the definitive reference for prescribers and patients who want the complete clinical detail. The broader Wegovy side-effect picture covers the more common gastrointestinal effects alongside this rarer visual risk.

When should you get urgent medical help for eye symptoms on semaglutide?

The threshold for seeking help should be low. Any of the following warrants a same-day call to your GP, an NHS 111 consultation, or (if vision changes are sudden) attendance at an emergency eye unit:

Sudden loss of vision in one eye, even if it is partial. Blurring that comes on quickly and does not improve after a few minutes. A dark shadow or missing patch appearing in your visual field. Pain behind the eye, particularly if accompanied by a change in vision. Double vision that is new and unexplained.

None of these should be attributed to treatment and left to resolve on their own. NAION in particular tends to present as painless and sudden, the absence of pain can make people hesitant to seek help, but it does not mean the situation is less urgent.

If you experience milder, transient blurring that improves on its own and does not worsen, mention it at your next review. Whatever you notice, reporting suspected side effects via the MHRA's Yellow Card scheme contributes to the post-market safety data that helps regulators track signals like NAION in real-world populations. You can do this yourself, it does not have to go through a prescriber. For related questions on semaglutide and the visual system, our pages on how Wegovy side effects can affect the eyes and the full range of Wegovy eye side effects cover the topic from slightly different angles.

Should vision history change your decision about starting Wegovy?

Not necessarily, but it should be part of the conversation. Wegovy is a licensed, effective weight-loss medicine, and for the right candidate the health benefits of sustained weight reduction are substantial. What the NAION data asks of prescribers is greater care in history-taking: specifically, whether someone has already had NAION in one eye (in which case the risk to the second eye may be higher), whether they have the anatomical risk factor of a small optic disc, or whether they have poorly controlled blood pressure or diabetes that independently raises optic nerve vulnerability.

None of these is an automatic exclusion, but they are clinical factors that affect the benefit-risk balance. A prescriber who knows your history can weigh this properly; self-selecting out of treatment because of a headline is as unhelpful as ignoring the risk entirely. The complete safety profile of semaglutide for weight loss puts this eye risk alongside all the others so you can read the full picture in one place. If you would like our prescribers to review your suitability, including any eye or visual history, check your eligibility through a free consultation.